513 related articles for article (PubMed ID: 22535624)
1. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
González GM
Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.
Halliday CL; Chen SC; Kidd SE; van Hal S; Chapman B; Heath CH; Lee A; Kennedy KJ; Daveson K; Sorrell TC; Morrissey CO; Marriott DJ; Slavin MA
Int J Antimicrob Agents; 2016 Oct; 48(4):453-8. PubMed ID: 27562696
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
Arredondo-García JL; Amábile-Cuevas CF;
J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
10. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Marco F; Pfaller MA; Messer SA; Jones RN
Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
[TBL] [Abstract][Full Text] [Related]
12. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp.
Kratzer C; Tobudic S; Schmoll M; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2006 Nov; 58(5):1058-61. PubMed ID: 16987867
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
15. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
16. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.
Fothergill AW; Rinaldi MG; Sutton DA
Med Mycol; 2009 Feb; 47(1):41-3. PubMed ID: 19107637
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
[TBL] [Abstract][Full Text] [Related]
19. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
20. Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.
Arendrup MC; Prakash A; Meletiadis J; Sharma C; Chowdhary A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
